ArticleBioorganic & medicinal chemistry letters2025
In vitro anti-influenza potential of glyceroglycolipids from cyanobacteria Limnospira fusiformis.
Article in Bioorganic & medicinal chemistry letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Previously, a chemical standardization method quantifying six fatty acids was established for Limnospira (formerly Arthrospira) authenticity and quality control. Since glyceroglycolipids constitute a significant source of fatty acids in Limnospira, a targeted phytochemical investigation was performed that resulted in the identification of two novel diacylated glycerol sulfoquinvosides and four known compounds. Notably, in vitro anti-influenza activity of isolated and analogous glyceroglycolipids, specifically two glyceroglycolipids, incorporating γ-linolenic acid and sulfoquinvose units tethered to a glycerol backbone, exhibited the highest anti-influenza activity. These findings suggest that the glyceroglycolipid-enriched fraction from Limnospira holds the potential for direct-acting antiviral properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.